Work Area: Transactions

Latest content

Drug royalty sales supercharged by sinking biotech valuations, says leading dealmaker

Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market

03 October 2022

Takeda continuing divestment spree by monetising unwanted oncology IP

The Japanese company is leading the pack in trend of commercialising de-prioritised assets

30 September 2022

BlackBerry hints at restart for licensing business as patent sale stalls

CEO John Chen tells investors that plans to rebuild the in-house operation are being finalised but says he remains confident a deal with Catapult IP will be done

29 September 2022

Covid and economic fears spur rising IP monetisation trend

Companies in more industries and sectors are looking to raise capital using their intellectual property as collateral

28 September 2022

Patent pools pass the antitrust test and are here to stay, say IAM event delegates

As long as key issues of concern are always addressed, collective licensing will continue to get regulatory sign-off

27 September 2022

Patent transactions in Q2 2022

Featured in Secondary Market Activity

Data from AST shows that wider economic uncertainties had an impact on secondary market activity between April and June with deal numbers falling to under 300

16 September 2022

Forma Therapeutics $1.1 billion buyout shows high demand for orphan drug IP

Patent-backed rare disease innovations secure more M&A/licensing investment than any pharma assets outside oncology

07 September 2022

Why the Unitary Patent is not uniform and how this will affect patent transactions

With the inauguration of the UP regime in 2023 and the effects that it will have on patent transactions and deals, companies should be up to speed on which national law will apply to their granted UPs and whether they would benefit from restructuring their European operations.

31 August 2022

$600 million BlackBerry patent deal still alive despite exit of key financial backer

Third Eye Capital syndicate due to provide $400 million for the purchase of the portfolio pulls out, but replacements are said to be on hand

31 August 2022

Merck’s $3.5 billion deal reflects surging interest in fast-moving RNA IP landscape

Innovations in the space are attracting growing attention from investors and Big Pharma

29 August 2022

Unlock unlimited access to all IAM content